Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1CNS 1

Conditions

Neuroblastoma 1Lymphoma 1Leukemia 1Immunologic Deficiency Syndromes 1Anemia 1

Interventions

Cytarabine 898Cyclophosphamide 893fludarabine 517venetoclax 475fludarabine phosphate 464Azacitidine 451Rituximab 418Methotrexate 414Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 284Vincristine 280Daunorubicin 279Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 228Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 203Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 176Radiotherapy 169Prednisone 161Mitoxantrone 160Lenalidomide 159Mercaptopurine 154

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × fosphenytoin × Other hematologic neoplasm × Clear all
NCT00801931 2019-03-27

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Columbia University

Phase 1/2 Terminated
1 enrolled 8 charts
CNSClassical hematologyLymphoidOther hematologic neoplasm

Anemia, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡